Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
22.45
+0.58 (2.65%)
At close: Apr 1, 2026, 4:00 PM EDT
21.33
-1.12 (-4.99%)
Pre-market: Apr 2, 2026, 8:15 AM EDT
Immunome Revenue
In the year 2025, Immunome had annual revenue of $6.94M, down -23.23%.
Revenue (ttm)
$6.94M
Revenue Growth
-23.23%
P/S Ratio
365.92
Revenue / Employee
$39,215
Employees
177
Market Cap
2.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.94M | -2.10M | -23.23% |
| Dec 31, 2024 | 9.04M | -4.98M | -35.50% |
| Dec 31, 2023 | 14.02M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.20B |
| Travere Therapeutics | 490.73M |
| Arcus Biosciences | 247.00M |
| Day One Biopharmaceuticals | 158.18M |
| Beam Therapeutics | 139.74M |
IMNM News
- 22 days ago - Immunome: Upcoming NDA, Valuation, And Investment Case - Seeking Alpha
- 27 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Immunome Reports Full Year 2025 Financial Results and Provides Business Update - Business Wire
- 5 weeks ago - Immunome to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire
- 3 months ago - Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 3 months ago - Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat - Seeking Alpha
- 3 months ago - Immunome Announces Pricing of Public Offering of Common Stock - Business Wire